bit.bio Raises $25 Million In Series D Funding As Human Cell Model Demand Surges 76%
By Amit Chowdhry ● Nov 4, 2026
bit.bio, a Cambridge, UK-based biotechnology company specializing in human cell programming, has raised $25 million in Series D funding to expand its portfolio of human cell models and meet growing demand from pharmaceutical companies, biotechnology businesses, and research organizations. The financing follows the company's Series C round earlier in 2026 and includes investments from existing backer M&G Investments and Dr. Jonathan Milner, founder and former CEO of Abcam.